A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous CSL730 in Healthy Caucasian and Japanese Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2018
At a glance
- Drugs M-230 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors CSL Behring
- 14 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Aug 2018 According to a Momenta Pharmaceuticals media release,the company expected to complete this study in 2019.
- 11 May 2018 Planned number of patients changed from 48 to 66.